We speak to Verona Pharma’s CEO Jan-Anders Karlsson to find out how the company is looking to tackle the challenges of COPD, a surprisingly overlooked disease.
AstraZeneca has seen three of its drugs approved by the Japanese regulator – a new indication for its cancer drug Lynparza, and two new combination therapies for patients with chronic obstr
Novartis has positive data for a two-drug asthma regimen that forms the backbone of its efforts to take on rival GlaxoSmithKline in the respiratory market.
Boehringer Ingelheim and Optimum Patient Care are launching a new patient registry, APEX COPD (Advancing the Patient Experience in COPD), to better understan
Spire Health has launched a research study on COPD exacerbations using continuous respiratory sensors to assess adherence and identify digital biomarkers preceding exacerbations.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
